Evidence map›Paper›PMID 37119524›Full record

ArticleVeterinary medicine and science2023

Near-complete genome of SARS-CoV-2 Delta variant of concern identified in a symptomatic dog (Canis lupus familiaris) in Botswana.

Wonderful T Choga, Samantha L Letsholo, Chandapiwa Marobela-Raborokgwe, Irene Gobe, Mbatshi Mazwiduma, Dorcas Maruapula, John Rukwava, Mary Gorettie Binta, Boitumelo J L Zuze, Legodile Koopile and 17 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Veterinary medicine and science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 3 countries.

Wonderful T ChogaResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Samantha L LetsholoBotswana National Veterinary Laboratory, Gaborone, Botswana.
Chandapiwa Marobela-RaborokgweBotswana National Veterinary Laboratory, Gaborone, Botswana.
Irene GobeFaculty of Health Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Mbatshi MazwidumaVetPro Consultants, Gaborone, Botswana.
Dorcas MaruapulaResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
John RukwavaKweneng Veterinary Clinic, Gaborone, Botswana.
Mary Gorettie BintaBotswana National Veterinary Laboratory, Gaborone, Botswana.
Boitumelo J L ZuzeResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Legodile KoopileResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Kedumetse SeruResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Patience MotshosiResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Ontlametse Thato BarengResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Botshelo RadibeResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Pamela Smith-LawrenceHealth Services Management, Ministry of Health and Wellness, Gaborone, Botswana.
Kutlo MachekeHealth Services Management, Ministry of Health and Wellness, Gaborone, Botswana.
Lesego Kuate-LereHealth Services Management, Ministry of Health and Wellness, Gaborone, Botswana.
Modisa S MotswalediFaculty of Health Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Mpaphi B MbulawaHealth Services Management, National Health Laboratory, Gaborone, Botswana.
Mogomotsi MatshabaPresidential COVID-19 Taskforce, Gaborone, Botswana.
Kereng V MasupuPresidential COVID-19 Taskforce, Gaborone, Botswana.
Shahin LockmanResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Roger ShapiroResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Joseph MakhemaResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Mosepele MosepeleResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Simani GaseitsiweResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.
Sikhulile MoyoResearch Laboratory, Botswana Harvard AIDS Institute Partnership Gaborone, Gaborone, Botswana.ORCID 0000-0003-3821-4592
Harvard University · USUniversity of Botswana · BWBotswana Harvard AIDS Institute Partnership · BWBotswana Vaccine Institute (Botswana) · BWMinistry of Health · BWSouthern African Development Community · BW

Funding

H3ABioNet: a sustainable African Bioinformatics Network for H3AfricaU41HG006941 · NHGRI · UNIVERSITY OF CAPE TOWN · PI MULDER, NICOLA · 2012 to 2017
$14.8M
INTERNATIONAL TRAINING IN AIDS-RELATED EPIDEMIOLOGYD43TW000004 · FIC · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 1988 to 2012
$13.4M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
Viral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682k
FIC NIH HHS D43 TW000004FIC NIH HHS D43 TW009610FIC NIH HHS K43 TW012350NHGRI NIH HHS U41 HG006941NIAID NIH HHS K24 AI131924NIAID NIH HHS K24 AI131928Wellcome Trust
6 · The paper itself

Abstract

We sought to investigate whether SARS-CoV-2 was present, and to perform full-length genomic sequencing, in a 5-year-old male crossbreed dog from Gaborone, Botswana that presented overt clinical signs (flu-like symptoms, dry hacking cough and mild dyspnoea). It was only sampled a posteriori, because three adult owners were diagnosed with SARS-CoV-2 infection. Next-generation sequencing based on Oxford Nanopore Technology (ONT) was performed on amplicons that were generated using a reverse transcriptase real-time polymerase chain reaction (RT-qPCR) of confirmed positive SARS-CoV-2 nasopharyngeal and buccal swabs, as well as a bronchoalveolar lavage with mean real cycle threshold (qCt) value of 36 based on the Nucleocapsid (N) gene. Descriptive comparisons to known sequences in Botswana and internationally were made using mutation profiling analysis and phylogenetic inferences. Human samples were not available. A near-full length SARS-CoV-2 genome (∼90% coverage) was successfully genotyped and classified under clade 20 O and Pango-Lineage AY.43 (Pango v.4.0.6 PLEARN-v1.3; 2022-04-21), which is a sublineage of the Delta variant of concern (VOC) (formerly called B.1.617.2, first detected in India). We did not identify novel mutations that may be used to distinguish SARS-CoV-2 isolates from the dog and humans. In addition to Spike (S) region mutation profiling, we performed phylogenetic analysis including 30 Delta sequences publicly available reference also isolated from dogs. In addition, we performed another exploratory analysis to investigate the phylogenetic relatedness of sequence isolated from dog with those from humans in Botswana (n = 1303) as of 31 March 2022 and of same sublineage. Expectedly, the sequence formed a cluster with Delta sublineages - AY.43, AY.116 and B.1.617.2 - circulating in same time frame. This is the first documented report of human-associated SARS-CoV-2 infection in a dog in Botswana. Although the direction of transmission remains unknown, this study further affirms the need for monitoring pets during different COVID-19 waves for possible clinically relevant SARS-CoV-2 transmissions between species.

Indexed as

COVID-19Dog DiseasesWolvesAnimalsBotswanaDogsHumansMalePhylogenySARS-CoV-2AfricaBotswanaCOVID-19dognext-generation sequencing (NGS)SARS-CoV-2

Identifiers

PMID37119524
PMCPMC10357236
OpenAlexW4367367556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.